Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term nintedanib safety in progressive fibrosing interstitial lung disease
2018-000525-32Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nintedanib in progressive pulmonary fibrosis (PPF), sponsored by Boehringer Ingelheim. Primary endpoint: Incidence of overall adverse events. Started Oct 2018; status: active.
02
Drugs
nintedanib
03
Conditions
progressive pulmonary fibrosis (PPF)
Beyond the preview
Go deeper on 2018-000525-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000525-32.